Astellas and Xinnovion Strike $1.3B Deal for CLDN18.2-Targeting ADC XNW27011

2025Year5Month30Astellas and Evopoint Biosciences Announce Exclusive Licensing Agreement: Astellas Acquires Novel Clinical-Stage Antibody-Drug Conjugate from Evopoint BiosciencesADC）XNW27011The exclusive development and commercialization rights globally (excluding mainland China, Hong Kong, Macao, and Taiwan).

 

XNW27011Is a new type of clinical stageADCDrug, TargetedCLDN18.2. Currently, the drug is undergoing trials in China forCLDN18.2Patients with expressed solid tumors1/2Phase clinical research, including patients with gastric cancer, gastroesophageal cancer, and pancreatic cancer.XNW27011Using proprietary topoisomeraseIInhibitor payload and linker technology, which has demonstrated clinical success in other approved cancer treatments.

Astellas in the development ofCLDN18.2in treatment methods, including the world's first approvedCLDN18.2Targeted TherapyVYLOY™。XNW27011Is expected to meet the current unmet patient needs and will expand Astellas' oncology pipeline, which currently includes different approaches.CLDNTargeted therapy, as well as therapies targeting other sitesADC。

 

According to the terms of the agreement,Evopoint Biosciences will receive1.3Hundreds of millions of dollars in upfront payments and is eligible to receive up to7000Million USD in recent payments,and additional milestone payments related to development, regulatory, and commercialization milestones, totaling up to13.4Hundreds of millions of dollars, and ifXNW27011Approved, based on royalty of net sales.

This collaboration is between innovative pharmaceutical companies in ChinaADCTechnology“Going Overseas”Another milestone event, highlighting the global pharmaceutical industry's recognition of China's innovation capabilities. WithCLDN18.2Continuous breakthroughs in targeted therapy are expected to bring more precise treatment options for patients with gastrointestinal tumors, ushering cancer treatment into a new era.